Do analysts rate BGMS or MAAQ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mana Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, BGMS or MAAQ?

Mana Capital Acquisition has lower revenue, but higher earnings than Cyclacel Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cyclacel Pharmaceuticals $750K 4.56 -$3M -$4.54 N/A Mana Capital Acquisition N/A N/A N/A N/A N/A

Is BGMS or MAAQ more profitable?

Mana Capital Acquisition's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Cyclacel Pharmaceuticals N/A -51.21% -44.00% Mana Capital Acquisition N/A N/A N/A

Do analysts prefer MYNZ or BGMS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MYNZ or BGMS more profitable?

Mainz Biomed's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Mainz Biomed N/A N/A N/A Cyclacel Pharmaceuticals N/A -51.21% -44.00%

Do analysts rate ANEB or BGMS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ANEB or BGMS more profitable?

Cyclacel Pharmaceuticals' return on equity of -51.21% beat Anebulo Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Anebulo Pharmaceuticals N/A -74.57% -68.96% Cyclacel Pharmaceuticals N/A -51.21% -44.00%

Do analysts prefer APLT or BGMS?

Applied Therapeutics currently has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Applied Therapeutics is more favorable than Cyclacel Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is APLT or BGMS more profitable?

Cyclacel Pharmaceuticals' return on equity of -51.21% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% Cyclacel Pharmaceuticals N/A -51.21% -44.00%

Do analysts recommend AIMD or BGMS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ainos 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cyclacel Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Cyclacel Pharmaceuticals (BGMS) Competitors

$0.62 -0.02 (-2.64%)

As of 03:54 PM Eastern

Compare

BGMS vs. MAAQ, MYNZ, ANEB, APLT, and AIMD

Should you buy Cyclacel Pharmaceuticals stock or one of its competitors? MarketBeat compares Cyclacel Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cyclacel Pharmaceuticals include Mana Capital Acquisition (MAAQ), Mainz Biomed (MYNZ), Anebulo Pharmaceuticals (ANEB), Applied Therapeutics (APLT), and Ainos (AIMD). These companies are all part of the "pharmaceutical products" industry.

How does Cyclacel Pharmaceuticals compare to Mana Capital Acquisition?

Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Mana Capital Acquisition (NASDAQ:MAAQ) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

Mana Capital Acquisition has lower revenue, but higher earnings than Cyclacel Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cyclacel Pharmaceuticals	$750K	4.56	-$3M	-$4.54	N/A
Mana Capital Acquisition	N/A	N/A	N/A	N/A	N/A

23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. Comparatively, 68.4% of Mana Capital Acquisition shares are owned by institutional investors. 23.8% of Cyclacel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Cyclacel Pharmaceuticals had 1 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 1 mentions for Cyclacel Pharmaceuticals and 0 mentions for Mana Capital Acquisition. Cyclacel Pharmaceuticals' average media sentiment score of 0.00 equaled Mana Capital Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Cyclacel Pharmaceuticals	Neutral
Mana Capital Acquisition	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mana Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Mana Capital Acquisition's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%
Mana Capital Acquisition	N/A	N/A	N/A

Summary

Cyclacel Pharmaceuticals beats Mana Capital Acquisition on 4 of the 7 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to Mainz Biomed?

Mainz Biomed (NASDAQ:MYNZ) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

In the previous week, Cyclacel Pharmaceuticals had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 1 mentions for Cyclacel Pharmaceuticals and 0 mentions for Mainz Biomed. Mainz Biomed's average media sentiment score of 0.00 equaled Cyclacel Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Mainz Biomed	Neutral
Cyclacel Pharmaceuticals	Neutral

23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by company insiders. Comparatively, 23.8% of Cyclacel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Mainz Biomed has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.4, indicating that its share price is 140% less volatile than the broader market.

Mainz Biomed's return on equity of 0.00% beat Cyclacel Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cyclacel Pharmaceuticals has higher revenue and earnings than Mainz Biomed. Cyclacel Pharmaceuticals is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	20.18	-$21.65M	-$65.60	N/A
Cyclacel Pharmaceuticals	$750K	4.56	-$3M	-$4.54	N/A

Summary

Mainz Biomed and Cyclacel Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals (NASDAQ:ANEB) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anebulo Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cyclacel Pharmaceuticals' return on equity of -51.21% beat Anebulo Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anebulo Pharmaceuticals	N/A	-74.57%	-68.96%
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%

Cyclacel Pharmaceuticals has higher revenue and earnings than Anebulo Pharmaceuticals. Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anebulo Pharmaceuticals	N/A	N/A	-$8.48M	-$0.19	N/A
Cyclacel Pharmaceuticals	$750K	4.56	-$3M	-$4.54	N/A

28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Comparatively, 23.8% of Cyclacel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Cyclacel Pharmaceuticals had 1 more articles in the media than Anebulo Pharmaceuticals. MarketBeat recorded 1 mentions for Cyclacel Pharmaceuticals and 0 mentions for Anebulo Pharmaceuticals. Anebulo Pharmaceuticals' average media sentiment score of 0.00 equaled Cyclacel Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Anebulo Pharmaceuticals	Neutral
Cyclacel Pharmaceuticals	Neutral

Anebulo Pharmaceuticals has a beta of -1.88, meaning that its share price is 288% less volatile than the broader market. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.4, meaning that its share price is 140% less volatile than the broader market.

Summary

Cyclacel Pharmaceuticals beats Anebulo Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to Applied Therapeutics?

Applied Therapeutics (NASDAQ:APLT) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.

Applied Therapeutics currently has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Applied Therapeutics is more favorable than Cyclacel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

98.3% of Applied Therapeutics shares are owned by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by insiders. Comparatively, 23.8% of Cyclacel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Cyclacel Pharmaceuticals had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for Cyclacel Pharmaceuticals and 0 mentions for Applied Therapeutics. Applied Therapeutics' average media sentiment score of 0.00 equaled Cyclacel Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Applied Therapeutics	Neutral
Cyclacel Pharmaceuticals	Neutral

Cyclacel Pharmaceuticals' return on equity of -51.21% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%

Applied Therapeutics has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.4, indicating that its stock price is 140% less volatile than the broader market.

Cyclacel Pharmaceuticals has lower revenue, but higher earnings than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
Cyclacel Pharmaceuticals	$750K	4.56	-$3M	-$4.54	N/A

Summary

Applied Therapeutics beats Cyclacel Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Cyclacel Pharmaceuticals compare to Ainos?

Ainos (NASDAQ:AIMD) and Cyclacel Pharmaceuticals (NASDAQ:BGMS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

Ainos has a beta of 2.41, suggesting that its stock price is 141% more volatile than the broader market. Comparatively, Cyclacel Pharmaceuticals has a beta of -0.4, suggesting that its stock price is 140% less volatile than the broader market.

Cyclacel Pharmaceuticals has a net margin of 0.00% compared to Ainos' net margin of -11,912.10%. Cyclacel Pharmaceuticals' return on equity of -51.21% beat Ainos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	-11,912.10%	-160.55%	-62.29%
Cyclacel Pharmaceuticals	N/A	-51.21%	-44.00%

23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 9.8% of Ainos shares are held by insiders. Comparatively, 23.8% of Cyclacel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Cyclacel Pharmaceuticals had 1 more articles in the media than Ainos. MarketBeat recorded 1 mentions for Cyclacel Pharmaceuticals and 0 mentions for Ainos. Ainos' average media sentiment score of 0.00 equaled Cyclacel Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Ainos	Neutral
Cyclacel Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cyclacel Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cyclacel Pharmaceuticals has higher revenue and earnings than Ainos. Ainos is trading at a lower price-to-earnings ratio than Cyclacel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$120K	128.94	-$14.77M	-$2.89	N/A
Cyclacel Pharmaceuticals	$750K	4.56	-$3M	-$4.54	N/A

Summary

Cyclacel Pharmaceuticals beats Ainos on 9 of the 12 factors compared between the two stocks.

Get Cyclacel Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BGMS vs. The Competition

Export

Metric	Cyclacel Pharmaceuticals	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$3.42M	$942.65M	$4.34B	$12.22B
Dividend Yield	N/A	4.84%	11.45%	5.89%
P/E Ratio	-0.14	1.47	22.03	24.02
Price / Sales	4.56	118.90	153.67	124.95
Price / Cash	N/A	20.06	39.06	53.76
Price / Book	0.44	7.92	14.91	6.33
Net Income	-$3M	-$4.05M	$115.37M	$337.11M
7 Day Performance	-18.22%	0.21%	-1.60%	-1.12%
1 Month Performance	-36.08%	1.06%	-2.26%	0.46%
1 Year Performance	N/A	45.76%	11.95%	29.16%

Cyclacel Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BGMS Cyclacel Pharmaceuticals	0.4638 of 5 stars	$0.62 -2.6%	N/A	N/A	$3.42M	$750K	N/A	14	News Coverage
MAAQ Mana Capital Acquisition	N/A	$1.98 flat	N/A	-40.5%	$16.09M	N/A	N/A	1	Gap Down
MYNZ Mainz Biomed	N/A	$1.76 -7.4%	N/A	+4.2%	$15.95M	$659.94K	N/A	30	High Trading Volume
ANEB Anebulo Pharmaceuticals	N/A	$0.39 flat	N/A	-73.7%	$15.92M	N/A	N/A	4
APLT Applied Therapeutics	1.4421 of 5 stars	$0.10 flat	$1.00 +870.9%	N/A	$15.86M	$1M	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BGMS) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cyclacel Pharmaceuticals (BGMS) Competitors

BGMS vs. MAAQ, MYNZ, ANEB, APLT, and AIMD

How does Cyclacel Pharmaceuticals compare to Mana Capital Acquisition?

Summary

How does Cyclacel Pharmaceuticals compare to Mainz Biomed?

Summary

How does Cyclacel Pharmaceuticals compare to Anebulo Pharmaceuticals?

Summary

How does Cyclacel Pharmaceuticals compare to Applied Therapeutics?

Summary

How does Cyclacel Pharmaceuticals compare to Ainos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGMS vs. The Competition

Cyclacel Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cyclacel Pharmaceuticals (BGMS) Competitors

BGMS vs. MAAQ, MYNZ, ANEB, APLT, and AIMD

How does Cyclacel Pharmaceuticals compare to Mana Capital Acquisition?

Which has higher valuation & earnings, BGMS or MAAQ?

Do institutionals & insiders hold more shares of BGMS or MAAQ?

Does the media prefer BGMS or MAAQ?

Do analysts rate BGMS or MAAQ?

Is BGMS or MAAQ more profitable?

Summary

How does Cyclacel Pharmaceuticals compare to Mainz Biomed?

Does the media prefer MYNZ or BGMS?

Do insiders & institutionals have more ownership in MYNZ or BGMS?

Which has more volatility & risk, MYNZ or BGMS?

Is MYNZ or BGMS more profitable?

Do analysts prefer MYNZ or BGMS?

Which has better earnings & valuation, MYNZ or BGMS?

Summary

How does Cyclacel Pharmaceuticals compare to Anebulo Pharmaceuticals?

Do analysts rate ANEB or BGMS?

Is ANEB or BGMS more profitable?

Which has stronger earnings & valuation, ANEB or BGMS?

Do insiders and institutionals have more ownership in ANEB or BGMS?

Does the media prefer ANEB or BGMS?

Which has more risk and volatility, ANEB or BGMS?

Summary

How does Cyclacel Pharmaceuticals compare to Applied Therapeutics?

Do analysts prefer APLT or BGMS?

Do insiders & institutionals believe in APLT or BGMS?

Does the media refer more to APLT or BGMS?

Is APLT or BGMS more profitable?

Which has more risk and volatility, APLT or BGMS?

Which has stronger valuation and earnings, APLT or BGMS?

Summary

How does Cyclacel Pharmaceuticals compare to Ainos?

Which has more volatility & risk, AIMD or BGMS?

Is AIMD or BGMS more profitable?

Do insiders and institutionals hold more shares of AIMD or BGMS?

Does the media refer more to AIMD or BGMS?

Do analysts recommend AIMD or BGMS?

Which has preferable earnings and valuation, AIMD or BGMS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGMS vs. The Competition

Cyclacel Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools